Jarushka Naidoo: Surgical outcomes of RATIONALE-315 (Neoadjuvant Tis + chemo in resectable NSCLC)

Jarushka Naidoo recently posted on X:

“Surgical outcomes of RATIONALE-315 (Neoadjuvant Tis+chemo in resectable NSCLC):

– 84% on this arm had surgery,
– No unacceptable delays (all within 8 weeks), less pneumonectomy,
– Nice data on no. of LN resected (12 and 13 in each arm).”

Source: Jarushka Naidoo/X

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), a Professor in RCSI, and an Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as the national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded, and cooperative group clinical trials.

She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.